Christopher Degnan
2023
In 2023, Christopher Degnan earned a total compensation of $733.7K as Former Chief Financial Officer at Galera Therapeutics, a 12% decrease compared to previous year.
Compensation breakdown
| Option Awards | $259,684 |
|---|---|
| Salary | $460,845 |
| Other | $13,200 |
| Total | $733,729 |
Degnan received $460.8K in salary, accounting for 63% of the total pay in 2023.
Degnan also received $259.7K in option awards and $13.2K in other compensation.
Rankings
In 2023, Christopher Degnan's compensation ranked 1,552nd out of 3,001 executives tracked by ExecPay. In other words, Degnan earned more than 48.3% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 1,552 out of 3,001 | 48th |
Division Manufacturing | 911 out of 1,645 | 45th |
Major group Chemicals And Allied Products | 590 out of 913 | 35th |
Industry group Drugs | 574 out of 876 | 35th |
Industry Pharmaceutical Preparations | 409 out of 634 | 36th |
Source: SEC filing on January 24, 2025.
Degnan's colleagues
We found three more compensation records of executives who worked with Christopher Degnan at Galera Therapeutics in 2023.
News
Galera Therapeutics CEO J Sorensen's 2023 pay slips 8% to $1.3M
January 24, 2025
Galera Therapeutics CEO J Sorensen's 2022 pay falls 46% to $1.4M
April 27, 2023
Galera Therapeutics CEO J Sorensen's 2021 pay slips 14% to $2.5M
April 28, 2022
Galera Therapeutics CEO J Sorensen's 2019 pay jumps 373% to $2.5M
April 27, 2020